Pharmaceutical industry – Page 33
-
BusinessJ&J to buy Abbott Medical Optics
Deal adds laser surgery and cataract lens replacements to J&J’s eyecare business
-
BusinessDanaher boosts diagnostics with Cepheid buyout
$4bn deal strengthens Danaher’s life sciences portfolio
-
BusinessFDA’s first Duchenne drug approval reveals schism
Oligonucleotide drug reaches market amid pressure from patient families and strife over ‘patient-focused drug development’ at the regulator
-
BusinessBrexit could push Japanese pharma out of the UK
Warnings that Japanese R&D investment in the UK is endangered by plans to leave the EU
-
BusinessHealthcare firms invest in Crispr gene editing technology
Crispr licence agreements open up opportunities in drug discovery
-
BusinessNovartis reshuffle puts 120 staff at risk
Commitment to gene and cell therapy treatments emphasised as unit broken up amid pharmaceutical division refocus
-
OpinionDon’t fear the Crispr
Does simple gene-editing mean the end of traditional medicinal chemistry? Probably not
-
BusinessFDA urges labs to test all blood donations for Zika
Agency has also given emergency authorisation to two new Zika blood tests
-
BusinessPfizer to buy Astrazeneca’s antibiotics
Deal tops up Pfizer’s late-stage development pipeline, but AZ will retain biological programmes
-
BusinessPfizer gambles on $14bn Medivation deal
Cancer specialist likely just one target in hunt for marketed drugs to offset patent expiries
-
OpinionPreparing for the future of pharma
Dave Allen discusses how scenario planning helps to define uncertainty in pharma
-
-
BusinessStandard antibody will bolster biopharma
New NIST reference material will help validate and compare analytical techniques
-
BusinessAmgen and Advaxis partner on immuno-oncology
Deal covers rights to system for building cancer therapies specific to a patient’s own tumours
-
BusinessJob cuts at Takeda, Boehringer and Arena
Hundreds of positions eliminated as companies re-evaluate R&D
-
BusinessCelgene and Jounce team up against cancer
Firms promise next-generation immuno-oncology as existing drugs rack up successes
-
BusinessJuno CAR-T trial suspended after patient deaths
Immunotherapy study restarted with amended pre-treatment protocol
-
OpinionTime for better incentives to keep drug costs low
Getting outraged at drug price hikes is all very well, but we need more constructive options
-
BusinessAll part of the service
Simon Hirst, founder of contract research organisation Sygnature, is the 2016 Chemistry World entrepreneur of the year
-
BusinessUnpicking doctor payments
Accepting even small meals from drug industry reps appears to influence doctors’ prescription rates